An arm rehabilitation system for exercising a user's arm. The system provides an arm support device moveable upon a support surface by a user's first arm. The arm support device has a main body configured to movably engage the support surface on one side and has a hand support portion on an opposing side at or toward one end of the body for supporting a user's hand of the first arm. A primary hand support formation protrudes from the hand support portion and a secondary hand support handle extends from the main body at or toward the periphery of the hand support portion. An adjustable switch support boom assembly is also mounted to the main body and has at least one operable user input component for generating an actuation signal in response to operation by the user. An onboard motion tracking system mounted to or within the main body is configured to sense motion of the main body to enable user interaction with an interactive computer system running an application program.
A63B 23/12 - Appareils d'exercice spécialement adaptés à des parties déterminées du corps pour les membres, c.-à-d. supérieurs ou inférieurs, p. ex. en même temps pour les membres supérieurs
The present invention relates to methods and peptides for the modulation of gap junction communication between cells. In particular the present invention relates to methods for modulating gap junction communication in mammalian cells, comprising treating the cells with an effective amount of a peptide having the amino acid sequence FHPSS (SEQ ID NO: 3), or a variant form thereof having at least 60% sequence identity with the amino acid sequence and being at least 4 amino acids in length.
A61K 38/00 - Préparations médicinales contenant des peptides
A61P 17/02 - Médicaments pour le traitement des troubles dermatologiques pour traiter les blessures, les ulcères, les brûlures, les cicatrices, les cheloïdes, ou similaires
ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (USA)
Inventeur(s)
Clinch, Keith
Crump, Douglas Ronald
Evans, Gary Brian
Hazleton, Keith Zachary
Mason, Jennifer Mary
Schramm, Vern L.
Tyler, Peter Charles
Abrégé
The invention relates to compounds of formula (I) that are inhibitors of hypoxanthine and/or guanine purine phosphoribosyltransferases and to pharmaceutical compositions containing the compounds, processes for preparing the compounds, and methods of treating diseases or conditions in which it is desirable to inhibit hypoxanthine and/or guanine purine phosphoribosyltransferases. Such diseases include malaria.
C07F 9/6561 - Composés hétérocycliques, p. ex. contenant du phosphore comme hétéro-atome du cycle contenant des systèmes de plusieurs hétérocycles déterminants condensés entre eux ou condensés avec un carbocycle ou un système carbocyclique commun, avec ou sans autres hétérocycles non condensés
ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (USA)
INDUSTRIAL RESEARCH LIMITED (Nouvelle‑Zélande)
Inventeur(s)
Schramm, Vern, L.
Clinch, Keith
Tyler, Peter, Charles
Evans, Gary, Brian
Furneaux, Richard, Hubert
Abrégé
The present invention discloses methods for treating bacterial infections in a subject comprising administering to the subject a sub-growth inhibiting amount of a 5'- methylthioinosine phosphorylase (MTIP) inhibitor, as well as assays for identifying such inhibitors, and compounds and pharmaceutical compositions comprising the inhibitors.
A61K 31/7076 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p. ex. nucléosides, nucléotides contenant des cycles à six chaînons avec l'azote comme hétéro-atome d'un cycle contenant des pyrimidines condensées ou non-condensées contenant des purines, p. ex. adénosine, acide adénylique
A61K 31/41 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à cinq chaînons avec plusieurs hétéro-atomes cycliques, l'un au moins étant l'azote, p. ex. tétrazole
A method for real-time RL and/or ROSL dose rate measuring in an environment exposed to a radiation source(s). The method comprises the steps of exposing a dosimeter to the environment for irradiation by the radiation source(s), the dosimeter comprising a phosphor-doped fluoroperovskite compound, sensing the RL or ROSL emitted light from the dosimeter during irradiation by the radiation source(s) and generating a representative light detection signal, and recording or generating a real-time measure of dose rate in the environment based on the light detection signal. A radiation dosimeter detection system comprising a phosphor-doped fluoroperovskite compound, the dosimeter coupled to a detector by an optical fibre. The detector comprises first and second optical stimulation sources that transmit light over the optical fibre to the dosimeter in first and second wavelength ranges. An optical detector senses light emitted from the dosimeter from which read-out dose information is generated.
A surround sound system for reproducing a spatial sound field in a sound control region within a room having at least one sound reflective surface. The system uses multiple steerable loudspeakers located about the sound control region, each loudspeaker having a plurality of different individual directional response channels being controlled by respective speaker input signals to generate sound waves emanating from the loudspeaker with a desired overall directional response. A control unit connected drives each of the loudspeakers and has pre-configured filters based on measured acoustic transfer functions for the room for filtering the input spatial audio signals to generate the speaker input signals for all the loudspeakers to generate sound waves with co¬ ordinated overall directional responses that combine together at the sound control region in the form of either direct sound or reflected sound from the reflective surface(s) of the room to reproduce the spatial sound field.
H04S 3/02 - Systèmes utilisant plus de deux canaux, p. ex. systèmes quadriphoniques du type matriciel, c.-à-d. dans lesquels les signaux d'entrée sont combinés algébriquement, p. ex. après avoir été déphasés les uns par rapport aux autres
G10L 19/00 - Techniques d'analyse ou de synthèse de la parole ou des signaux audio pour la réduction de la redondance, p. ex. dans les vocodeursCodage ou décodage de la parole ou des signaux audio utilisant les modèles source-filtre ou l’analyse psychoacoustique
H04R 5/02 - Dispositions spatiales ou structurelles de haut-parleurs
The invention relates to a process for the aminohydroxylation of alkenes using N-oxycarbamate reagents, e.g. N-acyloxycarbamate, N-alkyloxycarbonyloxycarbamate and N-aralkoxycarbonyloxycarbamate reagents. The invention particularly relates to an intermolecular aminohydroxylation reaction that can be carried out in the absence of added base. The invention also relates to novel N-oxycarbamate reagents that are stable crystalline materials. The process of the invention is useful in the synthesis of compounds having a vicinal amino alcohol moiety, such as biologically active compounds.
C07C 227/20 - Préparation de composés contenant des groupes amino et carboxyle liés au même squelette carboné à partir de composés contenant déjà des groupes amino et carboxyle ou leurs dérivés par des réactions impliquant des groupes amino ou carboxyle, p. ex. hydrolyse d'esters ou d'amides, par formation d'halogénures, de sels ou d'esters par hydrolyse d'acides aminés N-acylés ou de leurs dérivés, p. ex. hydrolyse de carbamates
C07D 207/18 - Composés hétérocycliques contenant des cycles à cinq chaînons, non condensés avec d'autres cycles, ne comportant qu'un atome d'azote comme unique hétéro-atome du cycle avec uniquement des atomes d'hydrogène ou de carbone liés directement à l'atome d'azote du cycle comportant une liaison double entre chaînons cycliques ou entre chaînon cyclique et chaînon non cyclique
C07D 207/02 - Composés hétérocycliques contenant des cycles à cinq chaînons, non condensés avec d'autres cycles, ne comportant qu'un atome d'azote comme unique hétéro-atome du cycle avec uniquement des atomes d'hydrogène ou de carbone liés directement à l'atome d'azote du cycle
C07D 491/048 - Systèmes condensés en ortho avec un seul atome d'oxygène comme hétéro-atome du cycle contenant de l'oxygène le cycle contenant de l'oxygène étant à cinq chaînons
The invention relates to an exercise system/device for exercising a user's upper limb. The exercise system/device is intended for use in rehabilitating patients suffering hemiparesis that causes one upper limb to be at least partially paralysed. For example, the exercise system/device can be used for neuroplastic retraining rehabilitation techniques for enabling patients to regain control of their paralysed upper extremities, including shoulders, elbows, wrists and fingers, but primarily their shoulders and elbows via larger arm movements. This is achieved through the use of an elongate handle and a motion sensing device associated with the handle for communicating the user's movements of the handle to a gaming system. Although the exercise system/device is primarily for rehabilitation of patients suffering hemiparesis, it will be appreciated that it may also be used by any person for bilateral training and exercising upper limbs.
G06F 3/033 - Dispositifs de pointage déplacés ou positionnés par l'utilisateurLeurs accessoires
A63F 13/06 - utilisant des moyens actionnés par le joueur pour commander la position d'une zone spécifique sur l'affichage
A63B 23/16 - Appareils d'exercice spécialement adaptés à des parties déterminées du corps pour les membres, c.-à-d. supérieurs ou inférieurs, p. ex. en même temps pour les membres supérieurs pour les mains ou les doigts
9.
3-HYDROXYPYRROLIDINE INHIBITORS OF 5'-METHYLTHIOADENOSINE PHOSPHORYLASE AND NUCLEOSIDASE
ALBERT EINSTEIN COLLEGE OF YESHIVA UNIVERSITY (USA)
INDUSTRIAL RESEARCH LIMITED (Nouvelle‑Zélande)
Inventeur(s)
Evans, Gary Brian
Longshaw, Alistair Ian
Schramm, Vern L.
Tyler, Peter, Charles
Abrégé
The present invention relates to 3-hydroxypyrrolidine compounds of the general formula (I) which are inhibitors of 5'-methylthioadenosine phosphorylase or 5'-methylthioadenosine nucleosidase. The invention also relates to the use of these compounds in the treatment of diseases or conditions in which it is desirable to inhibit 5'-methylthioadenosine phosphorylase or 5'-methylthioadenosine nucleosidase including cancer, and to pharmaceutical compositions containing the compounds.
A handheld measurement device (10) for enabling a user to measure a person's muscle strength and range of motion associated with a limb movement about a joint in a movement plane. The device comprises a contact surface (28) that is arranged to contact a part of the person's limb, a 3D orientation sensor that is arranged to sense the 3D orientation of the device in 3D space and generate representative 3D orientation signals during the limb movement, and a force sensor that is arranged to sense the force applied by the person's limb to the contact surface and generate representative force signals. A control system receives the 3D orientation and force signals and processes those signals to generate force data and angular rotation data.
A61B 5/103 - Dispositifs de mesure pour le contrôle de la forme, du dessin, de la dimension ou du mouvement du corps ou de parties de celui-ci, à des fins de diagnostic
G01B 9/10 - Goniomètres pour mesurer des angles entre des surfaces
An arm exercise system (10) comprising an arm trolley (14) having one or more support wheels and which is arranged to support a user's arm for movement over a surface via the wheel(s). The arm trolley (14) also has an actuator(s) associated with one or more of the wheel(s) and which are operable to apply a level of braking to resist movement of the wheel(s). The system (10) further comprises a motion tracking system (16) that is arranged to sense and track movement of the trolley (14) over the surface and generate representative position data relating to the movement of the trolley. A computer system (18) is arranged to receive the representative position data to enable a user (12) to interact with a program running on the computer system via movement of the arm trolley (14) over the surface.
A63B 23/12 - Appareils d'exercice spécialement adaptés à des parties déterminées du corps pour les membres, c.-à-d. supérieurs ou inférieurs, p. ex. en même temps pour les membres supérieurs
A61H 1/00 - Appareils pour l'exercice passifAppareils vibrateursDispositifs de chiropractie, p. ex. dispositifs pour appliquer des chocs au corps, dispositifs externes pour étirer ou aligner de façon brève des os non fracturés
A bilateral upper limb exercise device (10) for exercising a user's arms comprising a central mounting structure (12) that is mountable to a fixed surface or structure (15), left and right limb supports (14a,14b) for supporting the forearm and/or hand of a respective arm of the user, and a pair of articulated linkage arms (22a,22b) that are pivotably coupled to opposite sides of the central mounting structure (12) and which are arranged to support a respective limb support (14a,14b) for movement in at least two degrees of freedom in a two-dimensional (2D) movement plane. A mirroring mechanism is also operatively coupled to the articulated linkage arms (22a,22b) such that movement of the opposing limb support relative to a central line of symmetry of the device.
A63B 23/12 - Appareils d'exercice spécialement adaptés à des parties déterminées du corps pour les membres, c.-à-d. supérieurs ou inférieurs, p. ex. en même temps pour les membres supérieurs
A61H 1/00 - Appareils pour l'exercice passifAppareils vibrateursDispositifs de chiropractie, p. ex. dispositifs pour appliquer des chocs au corps, dispositifs externes pour étirer ou aligner de façon brève des os non fracturés
A swath beam acoustic transducer (100) for projecting and/or receiving acoustic swath beams (108). The transducer comprises an array of active acoustic elements (104) that are arranged to collectively provide an elongate concave radiation surface (106) with an associated acoustic aperture (110). The array of active acoustic elements (104) is operable to project and/or receive acoustic swath beams (108) via the radiation surface (106).
A process for the separation of carbon dioxide from gas mixtures is disclosed in which a metal oxide sorbent, which is used to capture and release carbon dioxide, is recycled. The process incorporates the regeneration of the carbon dioxide capture capacity of the metal oxide to maintain a high capture capacity over many cycles. The regeneration involves hydrating the metal oxide and then heating the resulting metal hydroxide under a gas atmosphere that is effective to suppress the dehydration of the hydroxide so that dehydration occurs at an elevated temperature. The regeneration may also be used independently from the carbon dioxide separation process to produce, from a metal hydroxide, a metal oxide having an enhanced resistance to attrition and fragmentation.
B01J 8/18 - Procédés chimiques ou physiques en général, conduits en présence de fluides et de particules solidesAppareillage pour de tels procédés les particules étant fluidisées
B01D 53/96 - Régénération, réactivation ou recyclage des réactifs
B01J 20/04 - Compositions absorbantes ou adsorbantes solides ou compositions facilitant la filtrationAbsorbants ou adsorbants pour la chromatographieProcédés pour leur préparation, régénération ou réactivation contenant une substance inorganique contenant des composés des métaux alcalins, des métaux alcalino-terreux ou du magnésium
The invention relates to a process for preparing compounds that are inhibitors of nucleoside phosphorylases and nucleosidases, in particular, compounds that have a methylene link between a nucleoside base analogue moiety of the molecule and a sugar analogue moiety, via an amino nitrogen of the sugar analogue moiety.
The invention relates to the use of angiogenic crystallin proteins to promote angiogenesis, wound healing and/or endothelial cell migration. Alpha A crystallin and βB2 crystallin have particular application in these methods. The crystallins will usually be in monomeric form. Typically, truncated form(s) of βB2 crystallin protein are utilized as can be prepared by partial hydrolysis of the protein by a protease enzyme such as elastase I. Methods for the purification of crystallin proteins from eye tissue are also described.
A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes
C07K 1/16 - ExtractionSéparationPurification par chromatographie
A61P 17/02 - Médicaments pour le traitement des troubles dermatologiques pour traiter les blessures, les ulcères, les brûlures, les cicatrices, les cheloïdes, ou similaires
C07K 14/435 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
A beam forming system (10) for acoustic or electromagnetic beams comprising one or more beam forming elements (2) that are arranged to provide a doubly ruled radiation surface.
H01Q 19/12 - Combinaisons d'éléments actifs primaires d'antennes avec des dispositifs secondaires, p. ex. avec des dispositifs quasi optiques, pour donner à une antenne une caractéristique directionnelle désirée utilisant des surfaces réfléchissantes où les surfaces sont concaves
H01Q 3/26 - Dispositifs pour changer ou faire varier l'orientation ou la forme du diagramme de directivité des ondes rayonnées par une antenne ou un système d'antenne faisant varier la phase relative ou l’amplitude relative et l’énergie d’excitation entre plusieurs éléments rayonnants actifsDispositifs pour changer ou faire varier l'orientation ou la forme du diagramme de directivité des ondes rayonnées par une antenne ou un système d'antenne faisant varier la distribution de l’énergie à travers une ouverture rayonnante
H01Q 15/16 - Surfaces réfléchissantesStructures équivalentes courbes suivant deux dimensions, p. ex. paraboloïdales
H04B 13/00 - Systèmes de transmission caractérisés par le milieu utilisé pour la transmission, non prévus dans les groupes
G01S 1/54 - Systèmes à faisceau étroit, produisant à un récepteur un signal enveloppe pulsé de l'onde porteuse du faisceau dont le rythme dépend de l'angle entre la direction du récepteur par rapport à la balise et une direction de référence issue de la baliseSystèmes de recouvrement à faisceau large définissant une zone étroite et produisant à un récepteur un signal enveloppe pulsé de l'onde porteuse du faisceau dont le rythme dépend de l'angle entre la direction du récepteur par rapport à la balise et une direction référence issue de la balise
18.
USE OF IONIC LIQUIDS FOR EXTRACTION OR FRACTIONATION OF LIPIDS
The invention relates to a process which employs an ionic liquid for extracting unsaturated lipophilic compounds from lipid containing feed materials. The process can be used for extracting polyunsaturated fatty acids, or their derivatives, from feed materials containing a mixture of fatty acids or their derivatives.
C07C 7/10 - Purification, séparation ou stabilisation d'hydrocarburesEmploi d'additifs par extraction, c.-à-d. purification ou séparation d'hydrocarbures liquides à l'aide de liquides
C11B 13/00 - Obtention de graisses, huiles ou acides gras à partir de résidus
An apparatus and method for measuring perfusion in a tissue. The method comprising the steps of recording images of the tissue under laser light, calculating a plurality of contrast images from the plurality of images of the tissue, determining a power spectrum of scattered light from the plurality of contrast images, and determining perfusion from the power spectrum. The apparatus comprises a digital video camera, a laser light source, and a processor arranged to operate the camera to produce a plurality of images with different exposure times, receive the plurality of images from the camera and process the images to determine a power spectrum and determine perfusion from the power spectrum.
ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (USA)
Inventeur(s)
Evans, Gary Brian
Furneaux, Richard Hubert
Greatrex, Ben William
Schramm, Vern L.
Tyler, Peter Charles
Abrégé
Azetidine analogues of nucleosidase and nucleoside phosphorylase inhibitors having the general formula (I), the use of these compounds as pharmaceuticals, pharmaceutical compositions containing the compounds, methods of treating certain diseases using the compounds, processes for preparing the compounds, and intermediates useful in the preparation of the compounds wherein W and X are each independently selected from hydrogen, CH2OH, CH2OQ and CH2SQ; Y and Z are each independently selected from hydrogen, halogen, CH2OH, CH2OQ, CH2SQ, SQ, OQ and Q; Q is an alkyl, aralkyl or aryl group each of which may be optionally substituted with one or more substituents selected from hydroxy, halogen, methoxy, amino, or carboxy; R1 is a radical of the formula (II) or R1 is a radical of the formula (III) A is selected from N, CH and CR2, where R2 is selected from halogen, alkyl, aralkyl, aryl, OH, NH2, NHR3, NR3R4 and SR5, where R3, R4 and R5 are each alkyl, aralkyl or aryl groups optionally substituted with hydroxy or halogen, and where R2 is optionally substituted with hydroxy or halogen when R2 is alkyl, aralkyl or aryl; B is selected from hydroxy, NH2, NHR6, SH, hydrogen and halogen, where R6 is an alkyl, aralkyl or aryl group optionally substituted with hydroxy or halogen; D is selected from hydroxy, NH2, NHR7, hydrogen, halogen and SCH3, where R7 is an alkyl, aralkyl or aryl group optionally substituted with hydroxy or halogen; E is selected from N and CH; G is a C1-4 saturated or unsaturated alkyl group optionally substituted with hydroxy or halogen, or G is absent; or a tautomer thereof, or a pharmaceutically acceptable salt thereof, or an ester thereof, or a prodrug thereof.
C07D 403/14 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant au moins trois hétérocycles
C07D 401/02 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles
C07D 401/04 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
C07D 401/06 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une chaîne carbonée contenant uniquement des atomes de carbone aliphatiques
C07D 405/14 - Composés hétérocycliques contenant à la fois un ou plusieurs hétérocycles comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle et un ou plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle contenant au moins trois hétérocycles
The invention relates to compounds which are immunomodulatory compounds and, in particular, can induce IL-12 secretion. The invention also relates to compositions containing the compounds, precursors, and prodrugs of these compounds, use of these compounds as adjuvants in combination with vaccines, and use of these compounds for treatment of diseases or conditions relating to infection, atopic disorders, or cancer.
A method of detecting interference in a received sample vector using hidden Markov modelling by first estimating noise variance, where estimating noice variance comprises the steps of receiving a sample vector of noise and interference, sorting the sample vector in the frequency domain by order of increasing magnitude to produce an ordered vector, finding a sub-vector of the ordered vector that minimises the distance from a noise measure, and estimating the noise variance.
NATIONAL INSTITUTE OF WATER AND ATMOSPHERIC RESEARCH LIMITED (Nouvelle‑Zélande)
POWER PROJECTS LIMITED (Nouvelle‑Zélande)
Inventeur(s)
Gardiner, Alister
Le-Ngoc, Lan
Caughley, Alan, James
Abrégé
A wave energy converter (10) for extracting useful energy from wave motion. The converter (10) comprises an active float (12) that is arranged to float on the water, and being arranged to heave and surge in response to wave motion acting on the active float, and an elongate reactive body (14) that is arranged to be suspended in a substantially submerged state into the water and having sufficient surface area and length such that it pitches in response to wave motion- acting on the reactive body. The active float (12) and reactive body (14) are pivotably coupled for pivotable movement relative to each other about a single pivot axis (16) in response to heaving and surging of the active float and pitching of the reactive body. The converter also comprises a power output system that is driven by the pivotable movement about the pivot axis to capture the useful energy.
F03B 13/12 - Adaptations des "machines" ou machines motrices pour une utilisation particulièreCombinaisons des "machines" ou machines motrices avec les appareils entraînés ou qu'ils entraînentCentrales électriques ou ensembles machine-appareil caractérisés par leur utilisation de l'énergie des vagues ou des marées
24.
ACYCLIC AMINE INHIBITORS OF 5'-METHYLTHIOADENOSINE PHOSPHORYLASE AND NUCLEOSIDASE
ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (USA)
Inventeur(s)
Gulab, Shivali, Ashwin
Abrégé
The present invention relates to compounds of the general formula (I) which are inhibitors of 5'-methylthioadenosine phosphorylase or 5'-methylthioadenosine nucleosidase. The invention also relates to the use of these compounds in the treatment of diseases or conditions in which it is desirable to inhibit 5'-methylthioadenosine phosphorylase or 5'-methylthioadenosine nucleosidase including cancer, and to pharmaceutical compositions containing the compounds.
ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (USA)
Inventeur(s)
Clinch, Keith
Evans, Gary Brian
Furneaux, Richard Hubert
Kelly, Peter Michael
Schramm, Vern L.
Tyler, Peter Charles
Woolhouse, Anthony David
Gulab, Shivali, Ashwin
Abrégé
The invention relates to compounds of the general formula (I) which are inhibitors of purine nucleoside phosphorylases (PNPs) and/or nucleoside hydrolases (NHs). The invention also relates to the use of these compounds in the treatment of diseases and infections including cancer, bacterial infections, protozoal infections, and T-cell mediated disease and to pharmaceutical compositions containing the compounds.
The use of compounds for promoting the healing of wounds, having the formula 1: where R is a straight or branched chain C1-C30 alkyl which may be substituted by one or more hydroxyl groups or halogen atoms, and may contain one or more epoxy groups. The wounds treatable include chronic wounds, such as cuts, scratches, abrasions, oral ulcers, stomach ulcers, ulcers from cancer therapy, diabetic foot ulcers, venous stasis ulcers, pressure ulcers, and burns, as well as wounds that result from ophthalmic surgery, cosmetic surgery, general surgery, treatment for keloids and hypertrophic scars (anti-scarring treatments).
A61K 31/164 - Amides, p. ex. acides hydroxamiques d'un acide carboxylique avec un aminoalcool, p. ex. céramides
A61P 17/02 - Médicaments pour le traitement des troubles dermatologiques pour traiter les blessures, les ulcères, les brûlures, les cicatrices, les cheloïdes, ou similaires
27.
EXTRACTION OF HIGHLY UNSATURATED LIPIDS WITH LIQUID DIMETHYL ETHER
A process for obtaining lipids containing highly unsaturated fatty acids from plant or animal material, including contacting the material with liquid dimethyl ether to give a dimethyl ether solution containing lipids and a residue of plant or animal material, separating the solution from the residue of plant or animal material, and recovering lipids from the solution.
An imaging system (100) for generating a three-dimensional image of a body part of a patient (102). The imaging system (100) comprises a sensor head (101) that is moved relative to the patient (102) by a robot (103) to conduct a scan of the body part. The sensor head (101) is displaced from the patient (102) and comprises a three-dimensional profiler that is arranged to obtain surface profile information and a radar device that is arranged to obtain radiation information. The imaging system (100) has a control system that is arranged to operate the three-dimensional profiler and radar device. The control system also receives and processes the radiation information and surface profile information to generate a three-dimensional image of the body part that has multiple image points by synthetically focusing the radiation information.
ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (USA)
Inventeur(s)
Furneaux, Richard Hubert
Tyler, Peter Charles
Evans, Gary Brian
Schramm, Vern L.
Kim, Kami
Fröhlich, Richard
Abrégé
This invention relates to compounds that are analogues of coformycin, pharmaceutical compositions containing the compounds, and methods of using the compounds for treating protozoan parasite infections, especially malaria.
C07H 19/23 - Radicaux hétérocycliques contenant au moins deux hétérocycles condensés entre eux ou condensés avec un système carbocyclique commun, non prévus dans les groupes
A61K 31/4188 - 1,3-Diazoles condensés avec des systèmes hétérocycliques, p. ex. biotine, sorbinil
A61K 31/55 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à sept chaînons, p. ex. azélastine, pentylènetétrazole
A61K 31/7052 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p. ex. nucléosides, nucléotides
C07H 5/10 - Composés contenant des radicaux saccharide dans lesquels les liaisons carbone-oxygène ont été remplacées par le même nombre de liaisons carbone-hétéro-atomes à des atomes d'halogènes, d'azote, de soufre, de sélénium ou de tellure au soufre, au sélénium ou au tellure au soufre
C07H 15/14 - Radicaux acycliques non substitués par des structures cycliques liés à un atome de soufre, de sélénium ou de tellure d'un radical saccharide
30.
METHODS OF TREATING DISEASES USING INHIBITORS OF NUCLEOSIDE PHOSPHORYLASES AND NUCLEOSIDASES
ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (USA)
Inventeur(s)
Furneaux, Richard Hubert
Tyler, Peter Charles
Evans, Gary Brian
Schramm, Vern L.
Abrégé
The invention relates to treating a disease or condition in which it is desirable to inhibit 5'-methylthioadenosine phosphorylase (MTAP) and/or 5'-methylthioadenosine nucleosidase (MTAN). The invention particularly relates to the co-administration of 5'-methylthioadenosine (MTA), or a prodrug of MTA, with one or more MTAP/MTAN inhibitors. Included among the diseases treatable are prostate cancer and head and neck cancer.
A process for fractionating the constituents of a solution obtained by extracting plant or animal material with an aqueous-organic solvent where the aqueous-organic solvent is a mixture of water and a water-miscible organic solvent, generally including the steps of contacting the solution with a near-critical fluid to produce a raffinate phase containing high polarity constituents and water, and a near-critical fluid phase containing low to medium polarity constituents, separating the near-critical fluid phase from the raffinate phase, and recovering the low to medium polarity constituents from the near-critical fluid phase and the high polarity constituents from the raffinate phase.
ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (USA)
ISIS INNOVATION LIMITED (Royaume‑Uni)
Inventeur(s)
Furneaux, Richard Hubert
Tyler, Peter Charles
Mee, Simon Peter Harold
Evans, Gary Brian
Schramm, Vern L.
Fleet, George
Abrégé
The invention relates to compounds of the formula (I), which are L-enantiomeric forms of nucleoside analogues, and to pharmaceutical compositions containing the compounds, methods of treating certain diseases, including cancer, bacterial infection, parasitic infection, and T-cell mediated diseases, using the compounds, processes for preparing the compounds, and intermediates useful in the preparation of the compounds.
C07D 207/04 - Composés hétérocycliques contenant des cycles à cinq chaînons, non condensés avec d'autres cycles, ne comportant qu'un atome d'azote comme unique hétéro-atome du cycle avec uniquement des atomes d'hydrogène ou de carbone liés directement à l'atome d'azote du cycle ne comportant pas de liaison double entre chaînons cycliques ou entre chaînons cycliques et chaînons non cycliques
A61K 31/4025 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à cinq chaînons avec un azote comme seul hétéro-atome d'un cycle, p. ex. sulpiride, succinimide, tolmétine, buflomédil non condensés et contenant d'autres hétérocycles, p. ex. cromakalim
C07H 5/04 - Composés contenant des radicaux saccharide dans lesquels les liaisons carbone-oxygène ont été remplacées par le même nombre de liaisons carbone-hétéro-atomes à des atomes d'halogènes, d'azote, de soufre, de sélénium ou de tellure à l'azote
C07D 255/02 - Composés hétérocycliques contenant des cycles comportant trois atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par les groupes non condensés avec d'autres cycles
A61P 33/02 - Antiprotozoaires, p. ex. pour le traitement de la leishmaniose, de la trichomonase, de la toxoplasmose
C07D 473/34 - Atome d'azote lié en position 6, p. ex. adénine
ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (USA)
Inventeur(s)
Furneaux, Richard Hubert
Tyler, Peter Charles
Evans, Gary Brian
Schramm, Vern L.
Clinch, Keith
Abrégé
The invention relates to compounds of the formula (I), which are L-enantiomeric forms of nucleoside analogues, and to pharmaceutical compositions containing the compounds, methods of treating certain diseases, including cancer, bacterial infection, parasitic infection, and T-cell mediated diseases, using the compounds, processes for preparing the compounds, and intermediates useful in the preparation of the compounds.
C07D 207/04 - Composés hétérocycliques contenant des cycles à cinq chaînons, non condensés avec d'autres cycles, ne comportant qu'un atome d'azote comme unique hétéro-atome du cycle avec uniquement des atomes d'hydrogène ou de carbone liés directement à l'atome d'azote du cycle ne comportant pas de liaison double entre chaînons cycliques ou entre chaînons cycliques et chaînons non cycliques
A61K 31/4025 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à cinq chaînons avec un azote comme seul hétéro-atome d'un cycle, p. ex. sulpiride, succinimide, tolmétine, buflomédil non condensés et contenant d'autres hétérocycles, p. ex. cromakalim
C07H 5/04 - Composés contenant des radicaux saccharide dans lesquels les liaisons carbone-oxygène ont été remplacées par le même nombre de liaisons carbone-hétéro-atomes à des atomes d'halogènes, d'azote, de soufre, de sélénium ou de tellure à l'azote
C07D 255/02 - Composés hétérocycliques contenant des cycles comportant trois atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par les groupes non condensés avec d'autres cycles
A61P 33/02 - Antiprotozoaires, p. ex. pour le traitement de la leishmaniose, de la trichomonase, de la toxoplasmose
C07D 473/34 - Atome d'azote lié en position 6, p. ex. adénine
34.
FUNCTIONALISED CARBON NANOTUBES AND METHODS OF PREPARATION
The preparation of dithioester functionalised carbon nanotubes (DTE-CNTs) is described. The DTE-CNTs are prepared by reacting suitably functionalised carbon nanotubes with a modified Grignard reagent. The DTE-CNTs are particularly useful as chain transfer agents in reversible addition fragmentation chain transfer (RAFT) polymerisation reactions, and polymer composites prepared using the DTE-CNTs are also described.
B82B 3/00 - Fabrication ou traitement des nanostructures par manipulation d’atomes ou de molécules, ou d’ensembles limités d’atomes ou de molécules un à un comme des unités individuelles
brevets